Shao Qian-Wen, Chen Bao-An, Zhu Liang-Jun, Du Juan, Shu Yong-Qian, Shao Ze-Ye
Department of Hematology, Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P. R. China.
Ai Zheng. 2006 Jan;25(1):29-33.
BACKGROUND & OBJECTIVE: LAK cells have been applied to purge minimal residual leukemia cells in allogeneic hematopoietic stem cell transplantation(AHSCT) in clinic practice. CD3AK cells belong to T lymphocytes activated by anti-CD3McAb. This study was to construct nitric oxide donor CD3AK/iNOS through transfecting inducible nitric oxide synthase (iNOS) gene into human CD3AK cells by retroviral vector, and investigate the cytotoxic activity of CD3AK/iNOS to leukemia cell lines K562 and K562/ADM.
The amphotropic packaging cell line PA317 transfected with iNOS gene was cultivated to obtain viral supernatant. Human peripheral blood mononuclear cells (PBMNCs) were isolated and activated by anti-CD3McAb and low dose of interleukin-2 (IL-2). CD3AK cells were incubated with viral supernatant. The amount of nitric oxide (NO) and the activity of iNOS in the cultured supernatant of CD3AK/iNOS were evaluated. The cytotoxic activities of CD3AK/iNOS and CD3AK cells to K562 and K562/ADM cells were evaluated by MTT assay.
The contents of NO excreted by CD3AK/iNOS and CD3AK cells were (378.60+/-41.57) micromol/L and (98.07+/-22.31) micromol/L, respectively (P<0.001); the activities of iNOS synthesized by CD3AK/iNOS and CD3AK cells were (20.77+/-2.49) U/ml and (9.81+/-1.96) U/ml, respectively (P<0.001). The cytotoxic activities of CD3AK/iNOS cells to K562 and K562/ADM cells were significantly stronger than those of CD3AK [(64.85+/-18.13)% vs. (45.66+/-17.46)%, P<0.05; (63.80+/-9.93)% vs. (47.85+/-12.01)%, P<0.05].
The content of NO and activity of iNOS synthesized and excreted by CD3AK/iNOS cells are largely increased compared with those of CD3AK cells. CD3AK/iNOS cells have more significant cytotoxic activity to K562 and K562/ADM cells than CD3AK cells, but its cytotoxic activities to K562 and K562/ADM cells are similar.
在临床实践中,淋巴因子激活的杀伤细胞(LAK细胞)已被应用于异基因造血干细胞移植(AHSCT)中清除微小残留白血病细胞。CD3AK细胞属于抗CD3单克隆抗体激活的T淋巴细胞。本研究旨在通过逆转录病毒载体将诱导型一氧化氮合酶(iNOS)基因转染到人CD3AK细胞中构建一氧化氮供体CD3AK/iNOS,并研究CD3AK/iNOS对白血病细胞系K562和K562/ADM的细胞毒活性。
培养转染iNOS基因的嗜异性包装细胞系PA317以获得病毒上清液。分离人外周血单个核细胞(PBMNCs),并用抗CD3单克隆抗体和低剂量白细胞介素-2(IL-2)激活。将CD3AK细胞与病毒上清液孵育。评估CD3AK/iNOS培养上清液中一氧化氮(NO)的含量和iNOS的活性。通过MTT法评估CD3AK/iNOS和CD3AK细胞对K562和K562/ADM细胞的细胞毒活性。
CD3AK/iNOS和CD3AK细胞分泌的NO含量分别为(378.60±41.57)μmol/L和(98.07±22.31)μmol/L(P<0.001);CD3AK/iNOS和CD3AK细胞合成的iNOS活性分别为(20.77±2.49)U/ml和(9.81±1.96)U/ml(P<0.001)。CD3AK/iNOS细胞对K562和K562/ADM细胞的细胞毒活性明显强于CD3AK细胞[(64.85±18.13)%对(45.66±17.46)%,P<0.05;(63.80±9.93)%对(47.85±12.01)%,P<0.05]。
与CD3AK细胞相比,CD3AK/iNOS细胞合成和分泌的NO含量及iNOS活性大幅增加。CD3AK/iNOS细胞对K562和K562/ADM细胞的细胞毒活性比CD3AK细胞更显著,但对K562和K562/ADM细胞的细胞毒活性相似。